医学
白细胞介素23
免疫学
乌斯特基努马
临床试验
克罗恩病
疾病
炎症性肠病
炎症
人口
白细胞介素17
炎症性肠病
内科学
肿瘤坏死因子α
环境卫生
英夫利昔单抗
作者
Alexander R. Moschen,Herbert Tilg,Tim Raine
标识
DOI:10.1038/s41575-018-0084-8
摘要
IL-12 and IL-23 are closely related cytokines with important roles in the regulation of tissue inflammation. Converging evidence from studies in mice, human observational studies and population genetics supports the importance of these cytokines in the regulation of mucosal inflammation in the gut in particular. Ustekinumab, a therapeutic antibody targeting both cytokines is now widely licensed for the treatment of Crohn's disease, including in Europe, the USA, Canada and Japan, whilst agents targeting IL-23 specifically are in late-phase clinical trials. We review the emerging understanding of the biology of IL-12 and IL-23, as well as that of their major downstream cytokines, including IL-17. In particular, we discuss how their biology has influenced the development of clinical trials and therapeutic strategies in IBD, as well as how findings from clinical trials, at times surprising, have in turn refocused our understanding of the underlying biology.
科研通智能强力驱动
Strongly Powered by AbleSci AI